Glenmark Therapeutics Enters OTC Constipation Market with Polyethylene Glycol 3350 Launch
核心洞察
Glenmark Therapeutics (搜索) has launched Polyethylene Glycol 3350 powder (17 grams/capful) as an over-the-counter constipation (搜索) treatment in the US market, comparable to MiraLAX®.
The company enters a lucrative market segment that generated approximately $555.7 million in annual sales for the period ending February 2025, according to Nielsen® syndicated data.
This strategic product introduction addresses growing demand for alternative suppliers in the constipation (搜索) treatment category, reinforcing Glenmark's commitment to expanding its OTC healthcare portfolio.
Glenmark Therapeutics (搜索) Inc., USA announced today the launch of Polyethylene Glycol 3350, Powder for Solution (17 grams/capful) as an over-the-counter treatment for constipation (搜索). The product enters the US market as a comparable alternative to Bayer HealthCare's MiraLAX®, addressing a significant therapeutic need in gastrointestinal health.
The launch comes at a time when the market for such treatments shows substantial commercial potential. According to Nielsen® syndicated data for the 52-week period ending February 22, 2025, the MiraLAX® Powder for Solution (17 grams) market achieved annual sales of approximately $555.7 million, indicating strong consumer demand for effective constipation (搜索) remedies.
"We are excited to announce the launch of Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful, addressing the growing demand for a new supplier in this category," said Marc Kikuchi, President & Business Head, North America. "This addition highlights our commitment to meeting market needs and providing high-quality over-the-counter solutions for our customers."
Product Profile and Market Position
Polyethylene Glycol 3350 functions as an osmotic laxative, drawing water into the colon to soften stool and increase bowel movements. The powder formulation dissolves in beverages for convenient administration, making it suitable for patients seeking non-stimulant constipation (搜索) relief.
Glenmark's entry into this therapeutic category represents a strategic expansion of its over-the-counter portfolio. The company emphasizes that while their product contains the same active ingredient as MiraLAX®, it is independently manufactured and not affiliated with Bayer HealthCare LLC.
Addressing Constipation: A Common Health Concern
Constipation (搜索) affects millions of Americans annually, with prevalence increasing among older adults and certain patient populations. Current treatment options include dietary modifications, increased fluid intake, and various laxative formulations, with osmotic laxatives like polyethylene glycol offering a non-stimulant approach to symptom relief.
The introduction of Glenmark's product provides healthcare providers and patients with an additional option in managing this common gastrointestinal condition. The company's formulation is marketed specifically for the indications listed in Glenmark's approved drug facts label.
About Glenmark Pharmaceuticals
Glenmark Pharmaceuticals Ltd. operates as a research-led global pharmaceutical company with presence across branded, generic, and OTC segments. The company focuses on respiratory, dermatology, and oncology therapeutic areas, with operations in over 80 countries.
Ranked among the top 100 biopharmaceutical companies by Scrip 100 based on pharmaceutical sales in 2023, Glenmark maintains 11 manufacturing facilities across four continents. The company has also demonstrated environmental commitment, with its Green House Gas emission reduction targets approved by the Science Based Target initiative in 2023, making it only the second pharmaceutical company in India to achieve this distinction.
For more information about the newly launched Polyethylene Glycol 3350 Powder for Solution, healthcare professionals and consumers can visit the company's dedicated product website at https://glenmarkpharma-us.com/peg3350.